Related Experiment Video
Updated: Jun 28, 2025
Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens
Published on: December 9, 2022
Progress in Biological Research and Treatment of Pseudomyxoma Peritonei
Xi Li1,2,3, Guodong Liu1,2,3, Wei Wu1,2,3
1Department of Geriatric Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Abstract:
Pseudomyxoma peritonei (PMP) is a rare disease characterized by extensive peritoneal implantation and mass secretion of mucus after primary mucinous tumors of the appendix or other organ ruptures. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is currently the preferred treatment, with excellent efficacy and safety, and is associated with breakthrough progress in long-term disease control and prolonged survival. However, the high recurrence rate of PMP is the key challenge in its treatment, which limits the clinical application of multiple rounds of CRS-HIPEC and does not benefit from conventional systemic chemotherapy. Therefore, the development of alternative therapies for patients with refractory or relapsing PMP is critical. The literature related to PMP research progress and treatment was searched in the Web of Science, PubMed, and Google Scholar databases, and a literature review was conducted. The overview of the biological research, treatment status, potential therapeutic strategies, current research limitations, and future directions associated with PMP are presented, focuses on CRS-HIPEC therapy and alternative or combination therapy strategies, and emphasizes the clinical transformation prospects of potential therapeutic strategies such as mucolytic agents and targeted therapy. It provides a theoretical reference for the treatment of PMP and the main directions for future research.
Insights
Pseudomyxoma peritonei (PMP) is a rare condition causing mucus buildup in the abdomen. While cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) shows promise, new therapies are needed due to PMP
Area of Science:
- Oncology
- Gastroenterology
Background:
- Pseudomyxoma peritonei (PMP) is a rare malignancy characterized by extensive peritoneal metastasis and mucin hypersecretion.
- The current standard treatment involves cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC).
- Despite CRS-HIPEC's efficacy, high recurrence rates remain a significant challenge, limiting treatment options.
Purpose of the Study:
- To review the current literature on Pseudomyxoma peritonei (PMP).
- To provide an overview of PMP's biological research, treatment status, and limitations.
- To explore potential alternative and combination therapeutic strategies for refractory or relapsing PMP.
Main Methods:
- A comprehensive literature search was conducted using Web of Science, PubMed, and Google Scholar.
- The review focused on biological research, current treatment modalities, and emerging therapeutic strategies for PMP.
- Emphasis was placed on CRS-HIPEC, alternative therapies, and targeted treatments.
Main Results:
- CRS-HIPEC offers significant long-term disease control and survival benefits for PMP.
- Conventional systemic chemotherapy is largely ineffective for PMP.
- Alternative strategies like mucolytic agents and targeted therapies show potential for refractory or relapsing cases.
Conclusions:
- Novel therapeutic strategies are critical for managing recurrent or refractory Pseudomyxoma peritonei.
- Mucolytic agents and targeted therapies represent promising avenues for clinical translation.
- Further research is essential to improve long-term outcomes for PMP patients.
More Related Videos
07:54Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
07:20Intraoperative Detection of Subtle Endometriosis: A Novel Paradigm for Detection and Treatment of Pelvic Pain Associated with the Loss of Peritoneal Integrity
Published on: December 21, 2012